pharma · NATCOPHARM
Natco Pharma
Natco Pharma: PE above historical average. ROTATIONAL regime.
Price
₹877.5
Price 2026-08-20
5 day
-2.68%
Short-term move
1 month
-8.77%
Medium-term
Regime
ROTATIONAL
68% confidence
Market cap
₹17.6k Cr
neutral sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's ROTATIONAL regime affect Natco Pharma (NATCOPHARM) in the pharma sector?”
Price chart
₹897
-12.85% over period
About Natco Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.5% over 14 days) — not a reliable pattern.
52-week position
Trading at 71.5% of 52-week high
Technicals
RSI 14
39
Trend
downtrend
50 DMA
Below
200 DMA
Below
Key metrics
P/E ratio
12.4
57th pct · 7 quarterly points (limited history)
P/B
1.9
ROE
16.9%
Moderate profitability — 16.9% ROE
Market cap
₹17.6k Cr
Revenue growth
-3960.0% YoY
Promoter
51.0%
52-week range
₹789 – ₹1,226.8
71.5% of high
RSI (14)
39.0
downtrend
vs 50 DMA
Below
DMA ₹920.55
Coverage
100/100
HIGH
Quick Take
Natco Pharma: PE above historical average. ROTATIONAL regime.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹8,570 | +0.8% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,438 | -1.4% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,180 | -2.2% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,608 | -3.3% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,400 | -0.9% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹412.5 | -1.8% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,332.9 | +0.6% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,820 | -5.0% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| NATCOPHARM Natco Pharma | ₹877.5 | -7.6% | 12.4 | 16.9% | -3960% | ₹17.6k Cr |
Tensions to watch
Promoter holding at 51.0% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹921 (+5%)
Trend reversal confirmation
Breaks below ₹834 (-5%)
Further downside risk
PE reverts to median of 11.6 (7 quarterly points (limited history))
Valuation normalization
Pharma sector entering leadership
Sector rotation signal